Nomad Power Solutions (NMAD) vs Oncolytics Biotech (ONCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nomad Power Solutions (NMAD) has outperformed Oncolytics Biotech (ONCY) over the past year, losing 11.2% versus a loss of 57.5%. Over five years, ONCY leads with a -75.5% price change compared with -77.2% for NMAD. Oncolytics Biotech is the larger company by market cap ($73.0 million vs $72.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NMAD | ONCY |
|---|---|---|
| Share price | $4.53 | $0.557 |
| Market cap | $72.94M | $73.03M |
| 1-day change | +6.09% | +2.31% |
| YTD return | +8.65% | -37.43% |
| 1-year return | -11.23% | -57.47% |
| 5-year return | -77.17% | -75.48% |
| EPS (TTM) | $-1.01 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.38 | $1.32 |
| 52-week low | $2.36 | $0.525 |
| Distance from 52-week high | -45.94% | -57.80% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +645.06% |
| Average volume | 273.42K | 1.08M |
| Shares outstanding | 16.10M | 131.12M |
| Employees | — | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NMAD has outperformed ONCY by 46.2 percentage points over the past year.
About Nomad Power Solutions
NMAD stock →NOMAD Power Solutions, Inc. develops utility-scale mobile energy storage systems on providing transportable solutions.
Health Care · Biotechnology: Pharmaceutical Preparations
About Oncolytics Biotech
ONCY stock →Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
NMAD vs ONCY FAQ
Which is bigger, Nomad Power Solutions or Oncolytics Biotech?
Oncolytics Biotech (ONCY) is larger, with a market capitalization of $73.03M compared with $72.94M for Nomad Power Solutions (NMAD).
Which stock has performed better over the past year, NMAD or ONCY?
NMAD returned -11.23% over the past 12 months, compared with -57.47% for ONCY (price return, excluding dividends). Past performance does not predict future results.
Are Nomad Power Solutions and Oncolytics Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.